ADIA Nutrition Stakes Claim in $6.7B Industry with Strategic Trademark Expansion
17 sept. 2024 10h00 HE
|
ADIA Nutrition
WINTER PARK, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADIA Nutrition Inc. (OTC Pink: ADIA) has announced the hiring of a prominent Winter Springs law firm to fortify its intellectual property...
ADIA Nutrition Appoints Dr. Richard Edwards, DO as Second Medical Director
10 sept. 2024 10h00 HE
|
ADIA Nutrition
WINTER PARK, Fla., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Adia Nutrition (OTC Pink: ADIA) is excited to announce the appointment of Dr. Richard Edwards, DO, as its second Medical Director. Dr. Edwards...
Tiziana Life Sciences Appoints New Chief Executive Officer
19 août 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Tiziana Life Sciences Granted FDA Fast Track Designation
24 juil. 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis
16 juil. 2024 08h37 HE
|
Trethera Corporation
LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
FDA Accepts Tiziana Life Sciences Fast Track Designation Submission for Treatment of Multiple Sclerosis
11 juin 2024 08h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Tiziana Life Sciences Announces Six-Month Qualitative Improvement in Neuroimaging in 80% of Multiple Sclerosis Patients Receiving Intranasal Foralumab
06 juin 2024 09h00 HE
|
Tiziana Life Sciences Ltd.
Qualitative improvements in PET imaging seen in 80% of non-active Secondary Progressive Multiple Sclerosis (na-SPMS) Expanded Access patients receiving intranasal foralumab for at least 6-months.FDA...
Tiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis Research
30 mai 2024 07h00 HE
|
Tiziana Life Sciences Ltd.
NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via...
Bragar Eagel & Squire, P.C. Is Investigating Zoetis, and Morgan Stanley and Encourages Investors to Contact the Firm
07 mai 2024 21h00 HE
|
Bragar Eagel & Squire
NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Zoetis Inc. (NYSE: ZTS),...
MS INVESTOR NOTICE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Morgan Stanley Investors to Inquire About Securities Class Action Investigation – MS
04 mai 2024 11h06 HE
|
The Rosen Law Firm PA
NEW YORK, May 04, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Morgan Stanley...